Crizotinib (Crizotinib) regular purchase channel inquiry in 2025

Crizotinib is a small molecule tyrosine kinase inhibitor that was originally developed to target tumors driven by ALK fusion genes. It has been widely used in the treatment of lung cancer. Its indications are mainly focused on patients with ALK-positive and ROS1-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). In clinical practice, patients must be diagnosed with ALK or ROS1 mutations through genetic testing before they can use crizotinib. This is also an important prerequisite for targeted therapy to be different from traditional chemotherapy.

In overseas markets, the price of the original drug crizotinib is relatively high, about more than RMB 10,000 per box, which fluctuates due to exchange rate fluctuations. But at the same time, some developing countries such as Bangladesh and Laos have launched generic drugs. The common specification is 250mg*60 pills. Each box may be sold for only about 2,000 yuan. The ingredients of the drug are consistent with the original drug, providing patients with a more cost-effective choice. However, there are authenticity and regulatory risks associated with cross-border drug purchases, and patients must be careful in screening.

In the Chinese market, the original drug crizotinib has been launched and included in the medical insurance catalog. Patients can purchase medicines through regular hospital pharmacies, medical insurance designated pharmacies, and some approved medical platforms. Since drugs are prescription drugs and must be purchased with a doctor's prescription, patients are not allowed to purchase them through informal channels to avoid buying counterfeit or improperly stored drugs, which will affect the therapeutic effect and safety.

At present, the domestic crizotinib original drug specifications are mainly 250 mg 60 tablets and 200 mg 60 tablets, and the price is about more than 10,000 yuan. However, after medical insurance reimbursement, the actual out-of-pocket expenditure will drop significantly. Some areas also have major illness pooling or secondary reimbursement policies to further reduce the financial burden on patients. In the future, as generic drugs gradually enter the Chinese market, prices may be further reduced, thereby increasing the popularity of medication.

Reference materials:https://go.drugbank.com/drugs/DB08865